JPWO2020160180A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160180A5 JPWO2020160180A5 JP2021544152A JP2021544152A JPWO2020160180A5 JP WO2020160180 A5 JPWO2020160180 A5 JP WO2020160180A5 JP 2021544152 A JP2021544152 A JP 2021544152A JP 2021544152 A JP2021544152 A JP 2021544152A JP WO2020160180 A5 JPWO2020160180 A5 JP WO2020160180A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- melanoma
- renal cell
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 58
- 206010006187 Breast cancer Diseases 0.000 claims 20
- 208000026310 Breast neoplasm Diseases 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 201000001441 melanoma Diseases 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 19
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 18
- 206010005949 Bone cancer Diseases 0.000 claims 17
- 208000018084 Bone neoplasm Diseases 0.000 claims 17
- 206010060862 Prostate cancer Diseases 0.000 claims 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 16
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 201000005787 hematologic cancer Diseases 0.000 claims 12
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 230000000973 chemotherapeutic effect Effects 0.000 claims 6
- 239000002254 cytotoxic agent Substances 0.000 claims 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims 6
- 238000011319 anticancer therapy Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 4
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002489 hematologic effect Effects 0.000 claims 4
- 229940043355 kinase inhibitor Drugs 0.000 claims 4
- 230000004777 loss-of-function mutation Effects 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims 2
- 229960004783 fotemustine Drugs 0.000 claims 2
- 239000003226 mitogen Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 2
- 239000003881 protein kinase C inhibitor Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 201000008261 skin carcinoma Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229960003181 treosulfan Drugs 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000009795 Microphthalmos Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000037432 Thymic tumor Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 201000011186 acute T cell leukemia Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 239000012649 demethylating agent Substances 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000014616 embryonal neoplasm Diseases 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940099472 immunoglobulin a Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000010478 microphthalmia Diseases 0.000 claims 1
- 201000003731 mucosal melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000036907 triple-positive breast carcinoma Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798406P | 2019-01-29 | 2019-01-29 | |
| US62/798,406 | 2019-01-29 | ||
| US201962881275P | 2019-07-31 | 2019-07-31 | |
| US62/881,275 | 2019-07-31 | ||
| US201962938415P | 2019-11-21 | 2019-11-21 | |
| US62/938,415 | 2019-11-21 | ||
| PCT/US2020/015723 WO2020160180A1 (en) | 2019-01-29 | 2020-01-29 | Compounds and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523074A JP2022523074A (ja) | 2022-04-21 |
| JPWO2020160180A5 true JPWO2020160180A5 (https=) | 2023-02-07 |
| JP2022523074A5 JP2022523074A5 (https=) | 2023-02-07 |
| JP7665518B2 JP7665518B2 (ja) | 2025-04-21 |
Family
ID=71841237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544152A Active JP7665518B2 (ja) | 2019-01-29 | 2020-01-29 | 化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230079819A1 (https=) |
| EP (1) | EP3917527B1 (https=) |
| JP (1) | JP7665518B2 (https=) |
| CN (1) | CN113645971B (https=) |
| AU (1) | AU2020214308A1 (https=) |
| ES (1) | ES3032327T3 (https=) |
| IL (1) | IL285177B2 (https=) |
| WO (1) | WO2020160180A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| WO2019152437A1 (en) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2020160100A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20230149414A1 (en) * | 2020-01-29 | 2023-05-18 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CA3167275A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN115867314A (zh) * | 2020-05-20 | 2023-03-28 | 福宏治疗公司 | 治疗癌症的方法 |
| WO2022079290A2 (en) * | 2020-10-16 | 2022-04-21 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Cullin ring ubiquitin ligase compounds and uses thereof |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| WO2022198043A1 (en) * | 2021-03-19 | 2022-09-22 | Foghorn Therapeutics Inc. | Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm |
| WO2023196565A1 (en) * | 2022-04-08 | 2023-10-12 | Foghorn Therapeutics, Inc. | Methods of treating cancer |
| CN119768400A (zh) * | 2022-11-11 | 2025-04-04 | 苏州信诺维医药科技股份有限公司 | 一种稠环化合物、其用途及含其的药物组合物 |
| WO2025082531A1 (en) * | 2023-10-20 | 2025-04-24 | Suzhou Zanrong Pharma Limited | Compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006005941A1 (en) * | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| EP2559455A1 (en) * | 2008-07-15 | 2013-02-20 | Novartis AG | Heteroaryl derivatives as DGAT1 inhibitors |
| CN103429571A (zh) * | 2010-12-22 | 2013-12-04 | 普渡制药公司 | 作为钠通道阻断剂的取代吡啶 |
| JP6554480B2 (ja) * | 2014-03-18 | 2019-07-31 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2018187614A1 (en) * | 2017-04-05 | 2018-10-11 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2018213422A1 (en) * | 2017-05-17 | 2018-11-22 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2019152437A1 (en) * | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022508155A (ja) * | 2018-11-21 | 2022-01-19 | フォグホーン セラピューティクス インコーポレイテッド | がんを治療する方法 |
| BR112021010453A2 (pt) | 2018-12-19 | 2021-08-24 | Leo Pharma A/S | Composto, e, composição farmacêutica |
| EA202192101A1 (ru) * | 2019-11-21 | 2021-12-09 | Фогхорн Терапьютикс Инк. | Соединения и их применение |
| EP4097096A4 (en) * | 2020-01-29 | 2024-02-28 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
-
2020
- 2020-01-29 ES ES20749261T patent/ES3032327T3/es active Active
- 2020-01-29 US US17/425,140 patent/US20230079819A1/en active Pending
- 2020-01-29 WO PCT/US2020/015723 patent/WO2020160180A1/en not_active Ceased
- 2020-01-29 IL IL285177A patent/IL285177B2/en unknown
- 2020-01-29 AU AU2020214308A patent/AU2020214308A1/en not_active Abandoned
- 2020-01-29 EP EP20749261.2A patent/EP3917527B1/en active Active
- 2020-01-29 CN CN202080025628.0A patent/CN113645971B/zh active Active
- 2020-01-29 JP JP2021544152A patent/JP7665518B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petroni et al. | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | |
| JPWO2020160180A5 (https=) | ||
| Lerner et al. | Mucosal Melanoma: new insights and therapeutic options for a unique and aggressive disease. | |
| Ortiz | Extracellular vesicles in cancer progression | |
| Galluzzi et al. | Immunological effects of conventional chemotherapy and targeted anticancer agents | |
| JP2025065346A5 (ja) | 組み合わせ物 | |
| JP2011144190A (ja) | 抗癌剤の効果増強剤 | |
| Manzoor et al. | Autophagy: a versatile player in the progression of colorectal cancer and drug resistance | |
| JP2008501630A6 (ja) | 抗癌剤の効果増強剤 | |
| CN106604719A (zh) | 用放射、氧化铈纳米颗粒、和化疗剂的组合治疗癌症 | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| UA77945C2 (en) | Use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders (variants), pharmaceutical composition (variants) | |
| Kerbel | Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs | |
| US20220267770A1 (en) | Compositions and methods of using c/ebp alpha sarna | |
| JPWO2021155262A5 (https=) | ||
| Möller et al. | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma | |
| Malaponte et al. | Detection of BRAF gene mutation in primary choroidal melanoma tissue | |
| Ladoire et al. | Associating immunotherapy and targeted therapies: facts and hopes | |
| JPWO2023009834A5 (https=) | ||
| AU2001251336B2 (en) | Methods and compositions for treating neoplasms | |
| Ooi et al. | RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update | |
| KR20210053242A (ko) | 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도 | |
| KR20260006616A (ko) | 마이크로펩타이드 miac의 응용 | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| ES2670596T3 (es) | Terapia de combinación para prevenir la formación del DCIS y la progresión hasta cáncer de mama |